Kolibri

Quick links to important sections

Kolibri

Treatment option: Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kolibri

Understanding Kolibri

Kolibri is a therapeutic intervention developed to address specific physiological imbalances. It belongs to a class of medications designed to interact with targeted biological pathways to manage or alleviate symptoms associated with chronic conditions.

Mechanism of Action

The primary function of Kolibri involves the modulation of specific cellular receptors. By binding to these sites, the medication influences the signaling processes that contribute to the progression of certain health issues. This targeted approach aims to restore a more balanced state within the affected systems of the body.

Therapeutic Intent

Kolibri is utilized as part of a comprehensive management plan. Its role is to support long-term health goals by addressing the underlying mechanisms of a condition rather than providing temporary relief. The integration of this therapy is typically based on an assessment of a patient's specific health profile and the nature of their symptoms.

Composition and Development

The formulation of Kolibri is the result of biochemical research focused on improving the precision of pharmacological treatments. It is designed to be metabolized efficiently by the body, ensuring that the active components reach the intended site of action while maintaining stability throughout the therapeutic process.

What side effects are possible with Kolibri?

Possible Side Effects and Safety Information

The safety profile of Kolibri, a fixed-dose combination of Acetaminophen and Tramadol, is structured by regulatory authorities to classify documented risks based on frequency and affected body systems. The information below is based strictly on official government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to their incidence rates documented in regulatory safety data:

Classification Examples of Documented Effects (System-Organ Class)
Very Common (Affecting ge 1/10) Nausea (Gastrointestinal); Dizziness, Somnolence (Nervous System)
Common (Affecting ge 1/100 to < 1/10) Constipation, Vomiting, Dry mouth (Gastrointestinal); Headache, Tremor (Nervous System); Confusion, Anxiety (Psychiatric); Sweating (Skin)
Uncommon (Affecting ge 1/1,000 to < 1/100) Hypertension, Palpitations (Cardiovascular); Hallucinations (Psychiatric); Elevated Liver Enzymes (Hepatobiliary)

Serious Adverse Reactions and Safety Constraints

Official labeling highlights certain clinically significant risks. Serious adverse reactions documented include Hepatotoxicity (Acute Liver Failure), associated with the Acetaminophen component, and Severe Respiratory Depression, linked to the opioid-related component.

Safety is formally restricted in specific contexts. The medicine is contraindicated in cases of severe Hepatic Impairment and severe Renal Impairment due to the potential for increased drug concentrations and organ damage. Additionally, it is not to be used in acute intoxication with certain CNS depressants or concurrently with Monoamine Oxidase Inhibitors (MAOIs).

Some effects, such as nausea and dizziness, are cited as more common at the start of treatment. The risk of physical and psychological dependence is officially documented as associated with long-term exposure.

This structured safety information provides a neutral overview of the medicine’s established risk profile, ranging from common, less severe effects to rare, critical safety concerns.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Kolibri is a medical emergency that requires immediate attention, even if symptoms are not yet apparent. The official overdose profile is defined by the combined toxicity of the Acetaminophen and Tramadol components.

Overdose Manifestation Category Documented Presentation Population-Specific Notes
Life-Threatening Risks Respiratory depression up to respiratory arrest, circulatory collapse, and acute liver failure leading to death (fatal outcomes). Accidental ingestion of even one dose by a child can be fatal due to the Tramadol component. The risk of liver injury is greater in patients with hepatic impairment.
Documented Symptoms Tramadol toxicity signs include somnolence, seizures/convulsions, and miosis (pinpoint pupils). Acetaminophen toxicity may initially present as nausea, vomiting, pallor, and abdominal pain. The risk of liver damage is associated with the use of Acetaminophen at doses that exceed 4,000 milligrams per day.

Required Emergency Action

Official regulatory documents mandate the following immediate actions for a suspected overdose:

  • Get emergency help at once if an overdose is suspected, even if you feel well.
  • Call emergency services immediately if there is slow or shallow breathing or difficulty waking up.
  • Treatment requires hospital monitoring and the administration of specific agents: Naloxone for reversal of respiratory depression and N-acetylcysteine (NAC) for managing Acetaminophen toxicity.
  • Patients must be transferred immediately to a specialized unit to maintain vital functions and perform required hepatic tests.

Therapeutic Uses of Kolibri

Kolibri is a fixed-dose combination analgesic commonly used across conditions presenting with acute episodes of significant discomfort. The preparation is indicated for managing acute pain that is severe enough to require an opioid analgesic, typically when simpler treatment options have been insufficient. This supportive relief is considered relevant in contexts marked by increased discomfort or tension.


Key Areas of Symptomatic Relief

This medication is applied across therapeutic domains where additional symptomatic support is needed, primarily addressing symptoms related to heightened physiological activity that may contribute to temporary functional strain. It is commonly used to help manage symptoms across conditions, including moderate to severe acute pain, symptoms related to postoperative discomfort, acute flare-ups of conditions like osteoarthritis, and associated manifestations of migraine headache and fever. It helps address symptom clusters that may become intense or disruptive, such as the high-intensity pain experienced post-surgery or following an injury. This assists with easing the overall symptom load.

“This combination assists with maintaining a sense of stability during periods when symptoms are more noticeable, supports general well-being during symptomatic phases.”


Quick Fact: Relief for Acute Pain

Property Description
Primary Symptom Moderate to severe acute pain
Benefit Focus Supportive symptomatic relief, supports comfort during symptomatic periods
Common Scenarios Postoperative discomfort, acute injury, pain unresponsive to non-opioids

Regulatory References

  1. DailyMed (NIH/NLM) Drug Label Information

Eligibility and Restrictions for Use

Kolibri (Acetaminophen/Tramadol FDC) is generally restricted to use in adults (18 years and older). Regulatory bodies strictly define the patient populations who are prohibited or restricted from using this medicine.


Contraindicated Populations (Must Not Use)

Population/Condition Restriction Basis (Official Labeling)
Pediatric Patients Contraindicated in children younger than 12 years of age and in those under 18 years following tonsillectomy/adenoidectomy.
Organ Impairment Contraindicated in patients with severe hepatic impairment or acute intoxication (alcohol, opioids).
Physiological Status Contraindicated in significant respiratory depression, acute/severe asthma, known gastrointestinal obstruction (e.g., paralytic ileus), or uncontrolled epilepsy.
Concurrent Therapy Contraindicated in patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOIs.

Restricted and Special Populations

Population/Condition Eligibility Status (Official Labeling)
Pregnancy/Lactation Not Recommended. Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome. Breastfeeding is not recommended.
Metabolic Risk Prohibited for CYP2D6 ultra-rapid metabolizers due to increased respiratory risk.
Older Adults (>75 years) Requires cautious use due to potential for age-related decline in organ function.

The official eligibility criteria are strictly defined by regulatory documents to prevent use in patients whose physiological status, age, or concurrent conditions introduce a high risk, or where safety has not been established.

What should I know about interactions with other medicines?

Kolibri (a brand name for sertraline) can interact with a wide range of prescription and non-prescription medicines, as well as certain supplements. It is essential to inform your healthcare provider about all substances you are currently taking before starting Kolibri or making any changes to your treatment plan. Some interactions can increase the risk of serious side effects, such as Serotonin Syndrome or bleeding complications.

️ Serotonin Syndrome Risk

Combining Kolibri with other medications that increase serotonin levels can lead to Serotonin Syndrome, a potentially serious condition. This includes, but is not limited to, the following drug classes and substances:

Interaction Type Examples of Interacting Medicines
Monoamine Oxidase Inhibitors (MAOIs) Phenelzine, Linezolid, Methylene blue. (Must not be used together)
Other Serotonergic Agents Other SSRIs, SNRIs (e.g., Venlafaxine), Tricyclic Antidepressants (TCAs), Triptans (for migraines), Opioids (e.g., Tramadol, Fentanyl), and the supplement St. John's wort.

Increased Bleeding Risk

Taking Kolibri concurrently with medicines that affect blood clotting may increase the risk of bleeding, particularly in the gastrointestinal tract. Caution and careful monitoring are required when used with:

Interaction Type Examples of Interacting Medicines
Anticoagulants Warfarin, Apixaban, Dabigatran, Rivaroxaban
Antiplatelet Drugs/NSAIDs Aspirin, Ibuprofen, Naproxen

Other Notable Interactions

Kolibri may also affect the metabolism or increase the concentration of other drugs, such as certain antipsychotics (e.g., Pimozide), antiarrhythmics (drugs affecting heart rhythm), and the anti-seizure medication Phenytoin. Additionally, consuming alcohol while taking Kolibri may worsen central nervous system side effects like drowsiness.

Mechanism of Action

Kolibri is a fixed-dose combination product containing the centrally-acting, synthetic opioid tramadol and paracetamol (acetaminophen).

The opioid component, tramadol, primarily modulates neurotransmission within the central nervous system (CNS) via a multimodal mechanism. The parent compound and its major active metabolite, O-desmethyl-tramadol (M1), function as agonists at the mu-type opioid receptor. Activation of this G-protein coupled receptor leads to a reduction in neuronal excitability, inhibiting the release of key neurotransmitters.

Simultaneously, tramadol acts as a weak inhibitor of the sodium-dependent noradrenaline transporter (NET) and the sodium-dependent serotonin transporter (SERT). This reuptake inhibition increases the synaptic concentrations of noradrenaline and serotonin in specific CNS pathways. These combined actions result in a downstream cascade that modulates descending inhibitory signaling from the brainstem, impacting the processing of afferent neural signals.

The non-opioid component, paracetamol, has a less defined central mechanism, involving the inhibition of specific cyclooxygenase (COX) isoforms within the CNS, which reduces the synthesis of certain local mediators. Its activity may also involve an interaction with the serotonergic system or the endocannabinoid system. The combination of these two compounds leads to synergistic physiological consequences, specifically the modulation of signal transduction in the nociceptive pathways.

Dosage and Administration Information

How to Use Kolibri: Official Administration Guidelines

The correct use of Kolibri is determined by its official labeling, which outlines the methods, schedules, and conditions for administration. This section summarizes the instructions for using the medicine as described in established clinical guidelines.


Administration Scope

Entity Official Instruction
Route of Administration Oral (Tablet, film-coated) and/or Intravenous (IV) Infusion (for Lyophilized powder or Concentrate).
Standard Dosing Initial dose (e.g., 12.5 mg) once daily, followed by a titration phase to a maintenance dose (e.g., 200 mg) once daily. Maximum dose is limited (e.g., 400 mg).
Frequency and Timing Oral forms are taken once daily (QD). IV Infusion may be administered cyclically (e.g., every 3 weeks or every 6 weeks). The drug may be taken with or without food.

Procedural Instructions

Oral Administration: Tablets must be swallowed whole using a liquid; the tablets must not be crushed, cut, or chewed. If a dose is missed, the patient should take the next scheduled dose at the usual time; do not double the dose. If vomiting occurs shortly after an oral dose, do not take an additional dose immediately.

IV Administration: Requires preparation steps including reconstitution of lyophilized powder with Sterile Water for Injection, followed by dilution into the specified infusion solution (e.g., 0.9% Sodium Chloride) to reach the labeled concentration. The resulting IV solution must be administered via infusion over a specified duration (e.g., 30 minutes).

Population Adjustments: Dosage adjustment is required for specific populations, including recommended dose reduction for patients with moderate hepatic or renal impairment, as outlined in the official labeling. Use in severe impairment may not be recommended.

Recent Clinical Evidence

Kolibri is the name given to several distinct clinical entities, including an investigational drug delivery system, a transcatheter heart valve system, and the designation for several independent clinical trials. As such, the clinical evidence is separated by context.

Evidence on the Drug Delivery System

Clinical data focuses on the performance of the Kolibri Mesh Nebulizer System, a device designed to deliver inhaled drug formulations. Studies indicate the system's ability to precisely control and monitor key inhalation parameters, such as flow rate and inhaled volume, in real time. This functionality is intended to support accurate dosing and reduce variability in drug deposition, which may enhance the reliability of clinical study results for the associated drug product.

COLIBRI Clinical Trial Evidence

The acronym COLIBRI (or variations thereof) has been used to label clinical studies investigating various therapeutic agents, which are not directly related to a single Kolibri drug product:

  • Type 2 Diabetes: The COLIBRI study explored the real-world use of once-weekly subcutaneous semaglutide in adult patients with Type 2 diabetes. Findings from this observational study reported reductions in glycated hemoglobin (HbA1c) and body weight after approximately 26 weeks of treatment.
  • Oncology: An oncology-focused COLIBRI trial investigated the safety and immune impact of a neoadjuvant combination of nivolumab and ipilimumab followed by chemoradiation for cervical squamous cell carcinoma. Preliminary data suggested the combination was tolerable and demonstrated an increase in certain immune cell markers (CD8+ cells).

It is important to note that the positive or negative outcomes reported in these clinical trial contexts (e.g., for semaglutide or nivolumab/ipilimumab) are specific to the study drugs being investigated, not the Kolibri device or a standalone Kolibri pharmaceutical agent.

Frequently Asked Questions (FAQ)

Common questions about Kolibri (FAQ)


Q: Why is Kolibri used for condition X when there are other options?

Kolibri is a specialized medication that combines two distinct pain-relieving agents into one tablet. It is generally described in official documents as being intended for moderate to severe acute pain when other single medications have not provided sufficient relief. This fixed-dose combination is designed to leverage the unique mechanisms of its components to modulate pain.


Q: How does Kolibri compare to similar drugs in its class?

Official studies and product information focus on the unique nature of this combination, which provides relief using two distinct pathways. Clinical data indicates the combination can achieve a a faster onset of pain relief compared to using the tramadol component by itself. The combined formulation is designed to leverage two distinct mechanisms of action.


Q: What makes Kolibri different from other treatments for its target condition?

The primary difference is the multimodal approach to pain relief provided by the two active ingredients in a single tablet. One component works as an opioid-related pain reliever, and the other is a non-opioid central analgesic. Official documents indicate this pairing is designed to leverage a synergistic effect by combining two distinct pharmacological mechanisms.


Q: How long does it typically take for Kolibri to start working?

Official product information, supported by regulatory studies, indicates that the onset of pain relief for this combination product is typically fast. Studies report relief has been measured to begin in approximately 17 minutes following administration.


Q: What should I expect to feel after I start taking Kolibri?

The therapeutic effect described in product information is the relief of acute pain. However, official information describes common experiences, especially when starting the medication, which can include central nervous system effects like dizziness and somnolence (drowsiness), as well as gastrointestinal effects such as nausea and constipation.


Q: How long is Kolibri typically taken for?

Regulatory materials indicate that Kolibri is specifically indicated for the management of acute pain. Due to this indication, official guidance suggests that the medicine should typically not be used for more than 5 days. The determination of the specific duration of use is the responsibility of the patient's healthcare provider.


Q: Are the side effects of Kolibri usually mild?

Official regulatory materials classify side effects into categories ranging from very common to serious. While many common effects (like dizziness or nausea) are often temporary, the medication carries high-level warnings for serious, life-threatening risks. These include the potential for fatal respiratory depression and acute liver failure (hepatotoxicity) associated with the two active components.


Q: Are there any specific foods or drinks that should be avoided with Kolibri?

Official product information states that the use of alcohol concurrent with this medication should be avoided, as it may worsen central nervous system side effects like drowsiness. Furthermore, some regulatory materials advise caution or avoidance of grapefruit and grapefruit juice.


Q: Why does Kolibri need to be stored at a specific temperature?

Official storage requirements mandate a specific temperature range, typically Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). This strict condition is necessary to ensure the medication maintains its strength and quality over time. Proper storage prevents the active chemical components from degrading, ensuring the medicine is effective when used.


Q: Why did my doctor choose Kolibri instead of another drug?

Official criteria for use are based on the medication's indication for moderate to severe acute pain that has not responded adequately to alternative treatments. The combination product is designed to leverage a synergistic effect. The healthcare provider relies on these regulatory criteria when determining appropriate treatment options.


Q: How is the dosage for Kolibri usually determined?

The dosage is determined by a healthcare provider based on the specific medical problem being addressed and the patient's individual needs. Regulatory documents include mandatory guidelines for dosage adjustment (typically reduction) for patients with moderate impairment of kidney or liver function.


Q: Is there a risk of overdose with Kolibri?

Yes, there is a risk of overdose. Official warnings highlight that accidental ingestion, particularly by children, can be fatal due to the tramadol component. Additionally, an overdose of the acetaminophen component can result in severe and potentially fatal damage to the liver, known as acute liver failure (hepatotoxicity).


Q: What is the official documentation for Kolibri called?

The complete official document that defines the drug’s approved use, safety, and administration is known by specific titles globally. In the United States, it is called the Full Prescribing Information (PI), and in Europe, it is known as the Summary of Product Characteristics (SmPC). This information is also summarized in the Patient Information Leaflet (PIL) or Medication Guide.


Q: Is Kolibri a new drug, or has it been used for a while?

Kolibri, which is the brand name for this specific combination of ingredients, is a long-established medication. The original branded version of this tramadol and acetaminophen combination received approval from the US FDA in 2001.


Q: Are there any non-drug ingredients in Kolibri I should know about (like allergens)?

Yes, the medication contains both active and inactive ingredients (excipients). Official regulatory documents include a full listing of these non-drug components in the Description section. For patients with known allergies or sensitivities, the complete official list of inactive ingredients must be consulted.


Q: Can Kolibri be taken if I am already taking an antibiotic?

Regulatory documents confirm that certain types of antibiotics can interact with Kolibri. For instance, antibiotics like Erythromycin or Rifampin can affect the specific liver enzymes responsible for processing the tramadol component of the medication. Regulatory information emphasizes that a healthcare provider must be informed of all concomitant medications, including antibiotics, due to the potential for drug interactions.


Q: Is it safe to consume caffeine while taking Kolibri?

Official drug interaction listings generally do not report a significant interaction between caffeine and Kolibri's active components. However, since the medicine can cause certain central nervous system effects, consuming caffeine may potentially worsen effects like nervousness or anxiety that are associated with the opioid component.


Q: Does Kolibri have a black box warning from the FDA?

Yes, official FDA labeling requires this combination product to carry a Boxed Warning, which is the most serious level of warning. This warning specifically highlights the critical risks of addiction, abuse, and misuse, as well as the potential for life-threatening respiratory depression and acute liver failure (hepatotoxicity).


Q: What is the regulatory status of Kolibri in major countries?

Kolibri is a prescription-only medication that has been formally reviewed and approved by government health authorities worldwide, including the US FDA and comparable European agencies. This classification means the medicine is strictly controlled and only dispensed under the guidance of a licensed practitioner.


Q: Is Kolibri a controlled substance?

Yes, due to the presence of the opioid-related tramadol component, this product is classified as a Schedule IV controlled substance by the US Drug Enforcement Administration (DEA). This classification indicates the medicine has an accepted medical use but also a potential for dependence and misuse.


Q: Is it possible to be allergic to Kolibri?

Yes, regulatory labeling strictly states that Kolibri is contraindicated (must not be used) if a patient has a known history of hypersensitivity (an allergic reaction) to either of the active ingredients (tramadol or acetaminophen) or to any of the other components used in the product.


Q: Can Kolibri be used alongside dietary changes?

The official instructions for taking Kolibri state that the tablets can be taken with or without food. There are generally no specific regulatory requirements or prohibitions regarding accompanying dietary changes. Guidance on nutrition and health, when combined with this medication, is typically provided by a healthcare professional.


How should Kolibri be stored and disposed of?

How to Store and Dispose of Kolibri (Acetaminophen/Tramadol)

The storage of Kolibri tablets must adhere to specific regulatory requirements to maintain product integrity and ensure safety.

Official Storage Conditions

Requirement Description
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess heat, moisture, and direct light. Do not freeze.
Packaging Store in the original container and keep it tightly closed.
Child Safety Due to the opioid component, store securely, out of the sight and reach of children.

Disposal Instructions

Outdated or unused medicine must not be kept. Regulatory agencies advise that disposal should primarily use a drug take-back program. If this option is unavailable, the tablets should be mixed with an undesirable substance (such as dirt) in a sealed container before being placed in the household trash. Do not dispose of Kolibri via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kolibri found in:

A-Z Index: